A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life

Jassem, Jacek; Krzakowski, Maciej; Roszkowski, K.; Ramlau, Rodryg; Słomiński, Jan Marek; Szczęsna, Aleksandra; Krawczyk, K; Możejko-Pastewka, Barbara; Lis, J; Miracki, K.

doi:10.1016/s0169-5002(01)00286-0

Cited by 28 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have shown that cancer treatments such as targeted therapies, radiotherapy and chemotherapy lead to improvement in symptoms such as cough and improvement in global QoL [85][86][87]. Of these, Bezjak et al [85] assessed respiratory symptoms and global QoL in 731 patients with NSCLC.…”

Section: Assessment Of Impactmentioning

confidence: 99%

Understanding cough and its management in lung cancer

Harle

Blackhall

Smith

et al. 2012

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

show abstract

Section: Assessment Of Impactmentioning

confidence: 99%

Understanding cough and its management in lung cancer

Harle

Blackhall

Smith

et al. 2012

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

show abstract

“…Its toxicity was mild, with grades 3-4 neutropenia occurring in 25% of patients, and grades 3-4 thrombocytopenia occurring in only 2% of patients [3]. When gemcitabine is administered in combination with monthly cisplatin, response rates are 28-54%, MSTs are 7.6-15.4 months, and 1-year survival rates are 35-61% [3][4][5][6][7][8]. Moreover, phases I and II trials of the combination of gemcitabine and carboplatin have shown response rate of 25-52% and MSTs of 7.4-15.4 months [9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer

Shirai¹,

Hirose²,

Noda³

et al. 2006

Lung Cancer

View full text Add to dashboard Cite

“…The remaining 314 records dealt with the LC13; however, of these, 74 records were excluded because they did not present original data obtained by means of the module. Consequently, n = 240 articles were considered clinical studies according to our definition and were included in further analyses …”

Section: Resultsmentioning

confidence: 99%

Use of the lung cancer–specific Quality of Life Questionnaire EORTC QLQ‐LC13 in clinical trials: A systematic review of the literature 20 years after its development

Koller

Warncke

Hjermstad

et al. 2015

Cancer

View full text Add to dashboard Cite

13 (QLQ-LC13) covers 13 typical symptoms of lung cancer patients and was the first module developed in conjunction with the EORTC core qualityof-life (QL) questionnaire. This review investigates how the module has been used and reported in cancer clinical trials in the 20 years since its publication. Thirty-six databases were searched with a prespecified algorithm. This search plus an additional hand search generated 770 hits, 240 of which were clinical studies. Two raters extracted data using a coding scheme. Analyses focused on the randomized controlled trials (RCTs). Of the 240 clinical studies that were identified using the LC13, 109 (45%) were RCTs. More than half of the RCTs were phase 3 trials (n 5 58). Twenty RCTs considered QL as the primary endpoint, and 68 considered it as a secondary endpoint. QL results were addressed in the results section of the article (n 5 89) or in the abstract (n 5 92); and, in half of the articles, QL results were presented in the form of tables (n 5 53) or figures (n 5 43). Furthermore, QL results had an impact on the evaluation of the therapy that could be clearly demonstrated in the 47 RCTs that yielded QL differences between treatment and control groups. The EORTC QLQ-LC13 fulfilled its mission to be used as a standard instrument in lung cancer clinical trials. An update of the LC13 is underway to keep up with new therapeutic trends and to ensure optimized and relevant QL assessment in future trials.

show abstract

A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life

Cited by 28 publications

References 17 publications

Understanding cough and its management in lung cancer

Understanding cough and its management in lung cancer

Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer

Use of the lung cancer–specific Quality of Life Questionnaire EORTC QLQ‐LC13 in clinical trials: A systematic review of the literature 20 years after its development

Contact Info

Product

Resources

About